Benralizumab Arm A + Benralizumab Arm B + Benralizumab Arm C + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Conditions
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Trial Timeline
Jun 25, 2014 → Apr 9, 2018
NCT ID
NCT02155660About Benralizumab Arm A + Benralizumab Arm B + Benralizumab Arm C + Placebo
Benralizumab Arm A + Benralizumab Arm B + Benralizumab Arm C + Placebo is a phase 3 stage product being developed by AstraZeneca for Moderate to Very Severe Chronic Obstructive Pulmonary Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02155660. Target conditions include Moderate to Very Severe Chronic Obstructive Pulmonary Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02155660 | Phase 3 | Completed |
Competing Products
20 competing products in Moderate to Very Severe Chronic Obstructive Pulmonary Disease